UPDATE: Tango Therapeutics Inc. (TNGX) PT Lowered to $16 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 28, 2022 7:00 AM EDT- TNG908 receives Fast Track designation, expects Phase 1/2 trial to start in 2Q 2022 -
- Pipeline programs progressing throughout 2022 -
- Strong cash position of $485 million expected to support operations into second half of 2024 -
CAMBRIDGE, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2021, and provided business highlights.
... More